LYKOS THERAPEUTICS lobbying for LYKOS THERAPEUTICS

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$90,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Budget/Appropriations

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).

Defense

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).

Health Issues

Fiscal Year 2026 Commerce, Justice, Science and Related Agencies Appropriations Act (issues related to potential improvements to Food & Drug Administration and Drug Enforcement Administration processes for rescheduling of controlled substances) (no bill number).

Veterans

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating innovative mental health challenges, including PTSD (no bill); Fiscal Year 2026 Military Construction, Veterans Affairs and Related Agencies Appropriations Act (issues related to therapeutics and implementation research and development) (no bill number).